Teva agrees to settle US states’ generic drug price‑fixing lawsuit
Teva Pharmaceutical Industries and its subsidiary Actavis have reached a settlement in principle with a coalition of 45 U.S. states, the District of Columbia and two territories over allegations that they conspired to inflate prices of dozens of generic medicines. The agreement, announced in mid‑November 2026, puts the antitrust case on hold but does not include any admission of wrongdoing and the financial terms were not disclosed. The settlement follows earlier state actions that have produced more than $566 million in total payouts to states from other generic‑drug makers.
Why it matters
The settlement removes the immediate litigation risk for Teva and may limit further exposure to state antitrust actions, but the undisclosed payment amount leaves investors uncertain about the cost impact. The case also highlights ongoing regulatory scrutiny of generic‑drug pricing, which could affect future profitability in the segment.
Key facts
- 1Teva and Actavis reached a settlement in principle with over 40 state attorneys general, the District of Columbia and two U.S. territories. news.bgov.com
- 2The lawsuit alleged Teva colluded to raise prices on about 112 generic drugs, with some hikes exceeding 1,000%. medicaldaily.com
- 3Judge Michael P. Shea suspended the proceedings after the parties notified the court of the deal. medicaldaily.com
- 4Financial terms of the settlement were not disclosed. finance.yahoo.com
- 5Earlier settlements with other generic manufacturers have totaled more than $566 million nationally. medicaldaily.com
- 6Teva’s stock fell 1.98% after the news of the settlement. tipranks.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.